

Jean-Michel Molina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5607726/publications.pdf>

Version: 2024-02-01

39
papers

1,748
citations

471509

17
h-index

315739

38
g-index

39
all docs

39
docs citations

39
times ranked

2583
citing authors

#	ARTICLE	IF	CITATIONS
1	Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age. <i>HIV Medicine</i> , 2023, 24, 27-36.	2.2	11
2	<i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. <i>Transplant Infectious Disease</i> , 2022, 24, e13770.	1.7	3
3	Successful cefiderocol therapy of severe infections due to difficult-to-treat <i>Pseudomonas aeruginosa</i> in two allogeneic hematopoietic stem cell transplantation recipients. <i>Annals of Hematology</i> , 2022, , 1.	1.8	3
4	High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting MRSA. <i>Aids</i> , 2022, 36, 1511-1520.	2.2	8
5	Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): A prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 102, 269-274.	3.3	5
6	Safety and efficacy of fumagillin for the treatment of intestinal microsporidiosis. A French prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 487-494.	3.0	13
7	Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥65 Years: Week 48 Results of a Phase 3b, Open-Label Trial. <i>Infectious Diseases and Therapy</i> , 2021, 10, 775-788.	4.0	29
8	Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. <i>Aids</i> , 2021, 35, 1061-1072.	2.2	13
9	Clinical characteristics, risk factors and outcome of severe Norovirus infection in kidney transplant patients: a case-control study. <i>BMC Infectious Diseases</i> , 2021, 21, 351.	2.9	5
10	<i>Cryptococcus neoformans</i> meningitis in kidney transplant recipients: A diagnostic and therapeutic challenge. <i>Medical Mycology Case Reports</i> , 2021, 32, 84-87.	1.3	8
11	Update on French recommendations for the treatment of uncomplicated <i>Neisseria gonorrhoeae</i> infections. <i>International Journal of STD and AIDS</i> , 2021, 32, 1081-1083.	1.1	5
12	Mortality of People Living with HIV in Paris Area from 2011 to 2015. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 373-380.	1.1	8
13	Complement C5 inhibition in patients with COVID-19 - a promising target?. <i>Haematologica</i> , 2020, 105, 2847-2850.	3.5	53
14	European confederation of medical mycology expert consultation: An ECMM excellence center initiative. <i>Mycoses</i> , 2020, 63, 566-572.	4.0	8
15	Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users' ambivalences. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 155-161.	1.2	21
16	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2020, 382, 1232-1243.	27.0	101
17	Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. <i>Lancet HIV</i> , 2019, 6, e655-e666.	4.7	20
18	Randomized study evaluating the efficacy and safety of switching from an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. <i>Aids</i> , 2019, 33, 1583-1593.	2.2	7

#	ARTICLE	IF	CITATIONS
19	Incidence, risk factors and outcome of multi-drug resistant <i>Acinetobacter baumannii</i> nosocomial infections during an outbreak in a burn unit. <i>International Journal of Infectious Diseases</i> , 2019, 79, 179-184.	3.3	36
20	A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. <i>Aids</i> , 2018, 32, 1431-1442.	2.2	72
21	Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections: Promises and Perils. <i>ACS Infectious Diseases</i> , 2018, 4, 660-663.	3.8	12
22	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e23-e34.	4.7	83
23	Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients. <i>Aids</i> , 2018, 32, 2291-2299.	2.2	20
24	Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis. <i>Aids</i> , 2018, 32, 2161-2169.	2.2	45
25	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 379.	7.4	486
26	Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight). <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2129-2136.	3.0	5
27	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2017, 4, e486-e494.	4.7	31
28	Infectious Zika virus in vaginal secretions from an HIV-infected woman, France, August 2016. <i>Eurosurveillance</i> , 2017, 22, .	7.0	33
29	Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. <i>HIV Clinical Trials</i> , 2016, 17, 63-71.	2.0	4
30	ITPA deficiency and ribavirin level are still predictive of anaemia in HCV/HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study). <i>Antiviral Therapy</i> , 2016, 22, 461-469.	1.0	0
31	Bladder Cancer in HIV-infected Adults: An Emerging Issue? Case-Reports and Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0144237.	2.5	9
32	Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. <i>Lancet Infectious Diseases</i> , 2015, 15, 387-396.	9.1	67
33	Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. <i>Clinical Infectious Diseases</i> , 2015, 61, 1328-1335.	5.8	34
34	Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial. <i>Journal of the International AIDS Society</i> , 2014, 17, 19551.	3.0	3
35	Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era. <i>International Journal of STD and AIDS</i> , 2014, 25, 1022-1028.	1.1	11
36	Bladder cancer in HIV-infected adults: an emerging concern?. <i>Journal of the International AIDS Society</i> , 2014, 17, 19647.	3.0	2

#	ARTICLE	IF	CITATIONS
37	Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. <i>Lancet, The</i> , 2008, 372, 646-655.	13.7	442
38	Comparison of Tests and Procedures to Build Clinically Relevant Genotypic Scores: Application to the Jaguar Study. <i>Antiviral Therapy</i> , 2005, 10, 479-487.	1.0	24
39	Detection of microsporidia in surface water: a one-year follow-up study. <i>FEMS Immunology and Medical Microbiology</i> , 2000, 29, 95-100.	2.7	8